Clinical effect of spleen aminopeptide on improving liver function damage and immune function in children with infant hepatitis syndrome

Table 1 Comparison of general data between the two groups (n, mean ± SD)

Group	Average age (d)	The average course of disease (d)	Patient weight (kg)	First symptoms
				Jaundice	Pneumonia	Diarrhea
Control group (50)	41.78 ± 4.32	11.34 ± 3.25	3.34 ± 0.25	36	8	6
Therapy group (50)	41.62 ± 4.66	11.31 ± 3.64	3.31 ± 0.64	35	10	5
χ2/t	0.169	0.043	-0.309	0.327
P value	0.866	0.965	0.758	0.849

Table 2 Comparison of liver function levels between the two groups (mean ± SD)

Group	TBIL (μmol/L)		DBIL (μmol/L)		Serum alanine transferase (U/L)
	Before therapy	After treatment	Before therapy	After treatment	Before therapy	After treatment
Control group (50)	172.34 ± 32.18	75.78 ± 9.32	50.34 ± 12.25	32.51 ± 9.82	79.93 ± 19.27	69.85 ± 7.04
Therapy group (50)	173.32 ± 29.63	53.62 ± 8.66	49.36 ± 13.64	16.87 ± 3.81	73.94 ± 21.23	43.37 ± 8.30
t	-0.158	12.317	0.378	10.499	1.477	17.204
P value	0.874	0.000	0.706	0.000	0.143	0.000

DBIL: Direct bilirubin; TBIL: Total bilirubin.

Table 3 Comparison of the immune level of the two groups of patients (mean ± SD)

Group	CD4+ (%)		CD3+ (%)		CD4+/CD8+ (%)
	Before therapy	After treatment	Before therapy	After treatment	Before therapy	After treatment
Control group (50)	32.78 ± 8.32	41.34 ± 10.25	52.51 ± 10.32	62.78 ± 10.32	0.94 ± 0.25	1.67 ± 0.12
Therapy group (50)	32.62 ± 8.66	48.26 ± 10.64	51.05 ± 10.11	73.62 ± 10.66	0.96 ± 0.24	2.49 ± 0.37
t	0.094	-3.312	0.715	-5.166	-0.408	-14.907
P value	0.925	0.000	0.477	0.000	0.684	0.000

Table 4 Comparison of clinical efficacy and complications between the two groups [n (%)]

Group	Cure	Improved	Ineffective	Effective	Skin rash	Cough and sputum	Elevated platelets		Gastrointestinal reaction
Control group (50)	24 (48.00)	14 (28.00)	12 (22.00)	38 (76.00)	2 (4.00)	2 (4.00)		1 (2.00)		3 (6.00)
Therapy group (50)	14 (28.00)	35 (70.00)	1 (2.00)	49 (98.00)	0	1 (2.00)		0		1 (2.00)
χ2				10.698						4.000
P value				0.001						0.046